Companies: UChicago, CDC
Drugs: GIP
GLP-1 usage statistics show broad uptake and mixed clinical signals
100% citation coverage3 peer-reviewed sources
GLP-1 usage statistics show that 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year, with 2.9% using it for weight loss. New research also highlights meaningful benefits alongside kidney, pancreas, and gastrointestinal risks, shaping the latest research on GLP-1 for pharma teams.
Intelligence Snapshot
Executive Summary
GLP-1 usage statistics show 4.5% past-year use overall, with 2.9% for weight loss and 1.7% exclusively for weight loss.
Key Insights
-
Latest research on GLP-1 shows meaningful weight-loss benefit, with a median 11.3 kg loss…
Latest research on GLP-1 shows meaningful weight-loss benefit, with a median 11.3 kg loss reported in one study .
-
Women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7%…
Women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7% among men .
-
Safety signals remain a key decision point, with reported associations that include lower…
Safety signals remain a key decision point, with reported associations that include lower dementia and addiction risk but higher kidney, pancreas, and gastrointestinal risk .
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Quick Answer
GLP-1 usage statistics show 4.5% past-year use overall, with 2.9% for weight loss and 1.7% exclusively for weight loss.
Key Questions
- How many people are taking GLP-1 for weight loss?
- What does the latest research on GLP-1 show about weight loss?
- What do the latest research on GLP-1 say about safety?
- What should pharma teams watch in the GLP-1 pipeline?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for GIP.
Unlock full calendar →Contents11 sections
GLP-1 usage statistics show broad uptake and mixed clinical signals
GLP-1 usage statistics show that 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year, with 2.9% using it for weight loss. New research also highlights meaningful benefits alongside kidney, pancreas, and gastrointestinal risks, shaping clinical decision-making for pharma teams.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for GLP-1, with GIP most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- GLP-1 usage statistics show 4.5% past-year use overall, with 2.9% for weight loss and 1.7% exclusively for weight loss.
- Latest research on GLP-1 shows meaningful weight-loss benefit, with a median 11.3 kg loss reported in one study.
- Women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7% among men.
- Safety signals remain a key decision point, with reported associations that include lower dementia and addiction risk but higher kidney, pancreas, and gastrointestinal risk.
IntelligenceCompetitive Intelligence
UChicago and CDC are directly implicated. Competitive pressure reads low — compare pipeline positioning and partnership scouting against signals in this story.
The data behind GLP-1 adoption
GLP-1 usage statistics show growing real-world adoption: 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year for any reason; 2.9% reported using them to support weight loss, with 1.7% using them exclusively for weight loss. These figures reflect a mix of diabetes, cardiovascular, and weight-management use cases. Physicians and researchers recognize that the drugs are highly effective for weight management and type 2 diabetes treatment, yet the data do not support a simple adoption narrative. Instead, usage patterns suggest segmented uptake tied to specific clinical needs and risk profiles.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance low for GLP-1. Expect implications for pricing, access, and launch sequencing.
Clinical evidence shows both benefit and risk
The latest research on GLP-1 paints a nuanced picture. Following GLP1 treatment, participants reported a median weight loss of 11.3 kg. Weight loss efficacy, however, varies by sex: women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7% among men.
The safety profile is more complex. GLP-1 medications are associated with a decreased risk of dementia and addiction, and an increased risk of kidney, pancreas, and gastrointestinal problems. This risk-benefit calculus will shape how pharma teams position GLP-1 drugs and how physicians segment patients for treatment. The evidence base supports continued attention to patient stratification and long-term monitoring of organ-specific outcomes.
IntelligenceStrategic Takeaways
GLP-1 usage statistics show 4.5% past-year use overall, with 2.9% for weight loss and 1.7% exclusively for weight loss. Latest research on GLP-1 shows meaningful weight-loss benefit, with a median 11.3 kg loss reported in one study . Women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7% among men .
Pipeline signals point to broader incretin competition
Retatrutide is a GIP, GLP-1, and glucagon receptor agonist being studied for type 2 diabetes. The emergence of multi-agonist mechanisms represents a meaningful shift in the competitive pipeline. For BD teams and investors, this matters because it suggests differentiation will increasingly hinge on receptor selectivity, durability, and tolerability rather than GLP-1 efficacy alone.
IntelligenceEvidence Quality
Grounded in 3 peer-reviewed sources.
Implications for pharma teams
For pharma teams, the key question is not whether GLP-1s matter, but how usage statistics, long-term studies, and combination-therapy data may reshape positioning in obesity and type 2 diabetes. The evidence supports continued attention to patient segmentation, risk monitoring, and the competitive advance of GIP-containing programs. Pharma strategists should monitor the clinical progress of multi-agonist molecules as they advance through trials, and track comparative safety and efficacy data as longer-term studies emerge.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07630454 | Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | NOT_YET_RECRUITING | PHASE4 | Yunlong Wang |
| NCT07625319 | Gut Hormones and Nutritional Status After a Standardized Meal. | COMPLETED | NA | Medical University of Bialystok |
| NCT07215559 | A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | RECRUITING | PHASE2 | Eli Lilly and Company |
| NCT07609160 | Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | NOT_YET_RECRUITING | NA | Acibadem University |
| NCT07169851 | A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | RECRUITING | PHASE2 | Eli Lilly and Company |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| Wonkwang University Hospital | GLP-1 | 1 |
| University of Arizona | GLP-1 | 1 |
| Yunlong Wang | GLP-1 | 1 |
| Chinese University of Hong Kong | GLP-1 | 1 |
| Lia Bally | GLP-1 | 1 |
| Ain Shams University | GLP-1 | 1 |
Timeline
- Not_Yet_Recruiting trial NCT07630454 (PHASE4)
- Recruiting trial NCT07215559 (PHASE2)
- Not_Yet_Recruiting trial NCT07609160 (NA)
- Recruiting trial NCT07169851 (PHASE2)
Frequently Asked Questions
How many people are taking GLP-1 for weight loss?
The cited survey found 2.9% used a GLP-1 or GLP-1/GIP medication to support weight loss, with 1.7% using it exclusively for that purpose.
What does the latest research on GLP-1 show about weight loss?
Following GLP1 treatment, participants reported a median weight loss of 11.3 kg. Women taking GLP-1 RAs lost an average of 11% of their starting weight, compared to 7% among men.
What do the latest research on GLP-1 say about safety?
The cited study links GLP-1 medications to lower dementia and addiction risk but higher kidney, pancreas, and gastrointestinal risk.
What should pharma teams watch in the GLP-1 pipeline?
Retatrutide is a GIP, GLP-1, and glucagon receptor agonist being studied for type 2 diabetes. Watch for longer-term studies, more granular usage-by-country data, and the progress of GIP/GLP-1 combination programs as they advance through clinical trials.
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About GLP-1
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow GIP developments
FDA glp-1 alerts and GIP pipeline updates, every Monday.
- Sources analyzed
- 3
- Evidence strength
- 94/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk — Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle…
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…